In 2023, Recursion Pharmaceuticals completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).
However, Recursion Pharmaceuticals has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
Metric (tCO2e) | 2023 | 2022 | 2021 | 2020 - 2017 |
---|---|---|---|---|
Total Scope 1 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 2 | ||||
Market-Based | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Location-Based | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 3 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Create your Tracenable account today and download up to 5 company datasets of your choice for free. No credit card required.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Recursion Pharmaceuticals’s data sources below and access millions more through our Disclosure Search.
Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.
In 2023, the total operational greenhouse gas (GHG) emissions of Recursion Pharmaceuticals amounted to 2,718 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2). a
Compared to 2022, the total operational greenhouse gas (GHG) emissions of Recursion Pharmaceuticals increased by 117.61%, suggesting that the company faced challenges in reducing its emissions from its core operations. a
In 2023, the total Scope 1 emissions of Recursion Pharmaceuticals were 854 metric tons of CO₂ equivalent (tCO₂e). a
Compared to the previous year (2022), Recursion Pharmaceuticals's Scope 1 emissions increased by 217.47%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations. a
In 2023, Recursion Pharmaceuticals reported Scope 2 greenhouse gas (GHG) emissions of 1,474 tCO₂e using the market-based method and 1,864 tCO₂e using the location-based method. a
In 2023, Recursion Pharmaceuticals reported its Scope 2 emissions using the market-based method and using the location-based method. a